Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.
Leigh Purvis, director of Health Services Research at AARP Public Policy Institute, addresses the burdens of high prescription drug costs on Medicare beneficiaries.
Transcript
How does the burden of high prescription drug costs among the Medicare population differ from the general population?
I think the biggest difference that we’re seeing in terms of high cost drugs for Medicare beneficiaries is that under Medicare Part D there is a lot of coinsurance which is where they are responsible for a percentage of the drug cost as opposed to a flat copayment, and that type of payment structure hasn’t stretched too other forms of insurance yet. So, we are seeing Part D beneficiaries being responsible for much more of the cost than we see in other forms of insurance.
How do Medicare beneficiaries usually handle being faced with the donut hole after coming employer-sponsored insurance, where they didn’t have to deal with it?
Unfortunately, we see a lot of people either walking away from the pharmacy counter or trying to find other ways of getting their prescription drugs which is a problem because they are obviously operating outside of the system or they’re not treating the conditions that need to be treated, and that can ultimately lead to higher health care costs down the road.
What impact do you see new treatments that are very effective, but very expensive, having on Medicare and patients?
I think both of them are being negatively affected. Innovation is great, but it’s only great if you can afford to use it and, unfortunately, that’s kind of the trade-off that we are facing right now and we want to make sure that we are having access to these innovative therapies. The Medicare program is a tax-payer funded program and the more it’s spending on these types of products, the more tax payers are spending on these types of products, the more beneficiaries that are being asked to spend on these types of products. Unfortunately, I think about these groups, MedPack included, that have come to the conclusion that it’s really unsustainable. It pushes us to a precipice where people can’t access the drugs that they need.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More